Protalix announces positive 12-month interim data from BRIDGE phase III study of pegunigalsidase alfa to treat fabry disease: Carmiel, Israel Friday, October 18, 2019, 18:00 Hrs [ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback